重新审视β受体阻滞剂在心血管医学中的作用
本综述基于当代随机试验和大型人群分析,重新评估β受体阻滞剂的适应证。文章强调慢性射血分数降低的心力衰竭和心绞痛仍为明确适应证,同时审视了在射血分数保留的心肌梗死、稳定性冠心病、射血分数保留的心力衰竭、一线降压治疗及围术期管理中常规使用受到质疑的近期研究。
要点
- 慢性射血分数降低的心力衰竭和心绞痛仍是β受体阻滞剂的明确适应证。
- 在射血分数保留的心肌梗死、稳定性冠心病、射血分数保留的心力衰竭中常规使用受到质疑。
- 一线降压治疗和围术期管理中的常规使用也受到近期研究挑战。
核心结论
- β受体阻滞剂的获益比既往认识更为细微,需基于基础病理、心室功能和症状负担个体化决策。
研究设计与样本
- 综述,基于当代随机试验和大型人群分析。
主要发现
- 慢性射血分数降低的心力衰竭和心绞痛仍为明确适应证。
- 近期研究质疑在射血分数保留的心肌梗死、稳定性冠心病、射血分数保留的心力衰竭、一线降压治疗及围术期管理中的常规使用。
临床怎么用
- 提供以适应证为导向的实用框架,指导处方与降阶梯治疗实践。
局限性
- 指出需要进一步证据来优化处方和降阶梯治疗实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Beta-blockers have long been a foundational pharmacotherapy in cardiovascular care across many disease conditions. However, the emergence of contemporary randomized trials and large population analyses has reshaped our understanding of their appropriate use. This review highlights well established indications, such as chronic heart failure with reduced ejection fraction and angina, while also examining recent studies that have questioned routine use in certain scenarios such as myocardial infarction in patients with preserved ejection fraction, stable coronary artery disease, heart failure with preserved ejection fraction, first-line antihypertensive therapy, and perioperative management. Evolving data suggest that benefits are more nuanced than previously recognized and must be individualized based on underlying pathology, ventricular function, and symptomatic burden. This article provides a practical, indication-focused framework and identifies areas where further evidence is needed to refine prescribing and deprescribing practices.
引用
- Sperry BW, Abdel Jawad M, Bhatt DL, et al. Refining the Role of Beta-Blockers in Cardiovascular Medicine. J Am Coll Cardiol. 2026. PMID: 42484585. doi:10.1016/j.jacc.2026.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。